SCHEMBL18656956

SCHEMBL18656956

O=C1CC(=O)N(C[C@H](F)c2ccccc2)C(=O)N1CC(F)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 7/20 0.49
▸ MEN1 O00255 6/20 0.49
▸ MAPT P10636 5/20 0.49
▸ USP2 O75604 2/20 0.49
▸ GAA P10253 2/20 0.49
▸ HSD17B10 Q99714 2/20 0.49
▸ HTT P42858 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ BLM P54132 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ RECQL P46063 1/20 0.44
▸ F2 P00734 1/20 0.37
▸ PLG P00747 1/20 0.37
▸ ELANE P08246 1/20 0.37
▸ CTSG P08311 1/20 0.37
▸ CMA1 P23946 1/20 0.37
▸ CTRC Q99895 1/20 0.37
▸ OPRM1 P35372 1/20 0.36
▸ ALDH1A1 P00352 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10158844 1.00 KMT2A (0.49) KMT2AMEN1MAPTUSP2GAA
SCHEMBL10158862 1.00 KMT2A (0.49) KMT2AMEN1MAPTUSP2GAA
SCHEMBL10159473 1.00 KMT2A (0.49) KMT2AMEN1MAPTUSP2GAA
SCHEMBL10158875 1.00 KMT2A (0.49) KMT2AMEN1MAPTUSP2GAA
SCHEMBL18656937 0.89 KMT2A (0.70) KMT2AMEN1MAPTUSP2GAA
SCHEMBL10159124 0.85 MAPT (0.41) KMT2AMEN1MAPTUSP2GAA
SCHEMBL10159234 0.85 MAPT (0.41) KMT2AMEN1MAPTUSP2GAA
SCHEMBL10159140 0.85 MAPT (0.41) KMT2AMEN1MAPTUSP2GAA
SCHEMBL10159017 0.84 MAPT (0.53) KMT2AMEN1MAPTUSP2GAA
SCHEMBL18250141 0.83 KMT2A (0.36) KMT2AMEN1MAPTUSP2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3144299-A1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Cambria Pharmaceuticals, Inc. (US) 2017-03-22 — — EP disclosed
Send feedback